Literature DB >> 12086338

Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans.

Krasimira Halacheva1, Maya V Gulubova, Irena Manolova, Dimitar Petkov.   

Abstract

Immunohistochemical light and electron microscopical analysis of surgical biopsies obtained from femoral and iliac arteries of patients with thromboangiitis obliterans (TAO) were performed to investigate the presence of tumour necrosis factor-alpha (TNF-alpha) and expression of the endothelial cell adhesion molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. Expression of ICAM-1, VCAM-1 and E-selectin was increased on endothelium and some inflammatory cells in the thickened intima in all TAO patients. Ultrastructural immunohistochemistry revealed contacts between mononuclear blood cells and ICAM-1-, and E-selectin-positive endothelial cells. These endothelial cells showed morphological signs of activation. The present data indicate that endothelial cells are activated in TAO and that vascular lesions are associated with TNF-alpha secretion by tissue-infiltrating inflammatory cells, ICAM-1-, VCAM-1- and E-selectin expression on endothelial cells and leukocyte adhesion via their ligands. The preferential expression of inducible adhesion molecules in microvessels and mononuclear inflammatory cells suggests that angiogenesis contributes to the persistence of the inflammatory process in TAO.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086338     DOI: 10.1078/0065-1281-00621

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  14 in total

Review 1.  Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.

Authors:  Nicola Maruotti; Francesco Paolo Cantatore; Domenico Ribatti
Journal:  Eur J Clin Pharmacol       Date:  2013-11-07       Impact factor: 2.953

2.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

3.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

4.  Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.

Authors:  Rongjian Zhang; Youhua Xu; Hong Fu; Juejin Wang; Lai Jin; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

5.  Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.

Authors:  Youhua Xu; Rongjian Zhang; Jie Chen; Qichun Zhang; Juejin Wang; Jue Hu; Xiaowei Guan; Lai Jin; Hong Fu; Bo Gui; Yuanyuan Guo; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

6.  [Addiction to tobacco and the consequences for the skin].

Authors:  M Krug; A Wünsche; A Blum
Journal:  Hautarzt       Date:  2004-03       Impact factor: 0.751

7.  Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients.

Authors:  R Dellalibera-Joviliano; E E Joviliano; J S Silva; P R B Evora
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

Review 8.  Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.

Authors:  Abhishek Vijayakumar; Rahul Tiwari; Vinod Kumar Prabhuswamy
Journal:  Int J Inflam       Date:  2013-09-11

Review 9.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12

10.  Macrophages and angiogenesis in rheumatic diseases.

Authors:  Nicola Maruotti; Tiziana Annese; Francesco Paolo Cantatore; Domenico Ribatti
Journal:  Vasc Cell       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.